Clinical Research & Trial

Agency Sponsored Trials

Medical Oncology

Aspirin for Dukes C and High Risk Dukes B colorectal cancers-An international, Multi centre, Double blind, Randomized Placebo Controlled Phase III Trial – INDOX, Dr.B.Sivanesan

Radation Oncology

• Resource sparing curative treatment for Rectal Cancer – IAEA, Dr. M. Nagarajan
• A randomized multicenter trial of accelerated hypo – vs. normo–fractionated radiotherapy for head and neck squamous cell carcinoma (IAEA-HYPNO trial) – IAEA, M. Nagarajan
• Role of Human Papillomavirus Infection and other co-factors in the Aetiology of Head and Neck cancer India and Europe – WHO/IARC/ICMR, M. Nagarajan

Company Sponsored Trials

Medical Oncology

• Prospective, multi-centre, randomized, open-label, two-arm, parallel group, active control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of XXXXX/ Avastin™ when given intravenously in patients with Metastatic colorectal cancer – Dr. B. Sivanesan
• A Multi-center, randomized, double-blind, vehicle-controlled, phase-2 trial to evaluate the efficacy and safety of two concentrations of topical povidone-iodine nail solution (VBP-926) for the treatment of chemotherapy-associated paronychia in cancer patient– Dr. B. Sivanesan
• A Phase II/III Pivotal, Open-label, Randomized, 3Arm Study to Assess the Efficacy of LNP3794 Monotherapy or in Combination with Docetaxel, Compared with Docetaxel Alone, in Patients with RAS Mutation Positive Locally Advanced and Metastatic Non-Small Cell Lung Cancer – Dr. B. Sivanesan
• Prospective, multi-centre, randomized, open-label, two arm, parallel group, active-control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of XXXX/ Herceptin®(HerclonTM) when given intravenously in patients with Metastatic HER2-Over expressing Breast Cancer – Dr. A. Rajkumar

Radation Oncology

A Phase III, open-label,Randomized, Multi-center study of the effects of Leukocyte Interleukin, injection[xxxxxx} plus standard of care (Surgery + Radiotherapy or Surgery+Concurrent Chemoradiotherapy) in subjects with Advanced primary Squamous Cell Carcinoma of the oral cavity/Soft palate versus standard of care only – CEL SCI, Dr. M. Nagarajan

Heamato Oncology

• Observational Follow up for patient who has received BCD-020 (rituximab, CJSC BIOCAD, Russia) / Mabthera for CD20-positive indolent non-Hodgkin lymphoma in BIORIX study –
  Dr. B. Sivanesan
• A Phase 3 Randomized, Controlled, Open-Label Study of Selinexor, Bortezomib, and Dexamethasone (SVD) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) – Dr. B. Sivanesan
• SADAL: A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma (DLBCL) – Dr. B. Sivanesan

SeeLess